Literature DB >> 19230141

Phosphorylation of skeletal muscle calsequestrin enhances its Ca2+ binding capacity and promotes its association with junctin.

Nicole A Beard1, Lan Wei, Stephanie N Cheung, Takashi Kimura, Magdolna Varsányi, Angela F Dulhunty.   

Abstract

Calcium signaling, intrinsic to skeletal and cardiac muscle function, is critically dependent on the amount of calcium stored within the sarcoplasmic reticulum. Calsequestrin, the main calcium buffer in the sarcoplasmic reticulum, provides a pool of calcium for release through the ryanodine receptor and acts as a luminal calcium sensor for the channel via its interactions with triadin and junctin. We examined the influence of phosphorylation of calsequestrin on its ability to store calcium, to polymerise and to regulate ryanodine receptors by binding to triadin and junctin. Our hypothesis was that these parameters might be altered by phosphorylation of threonine 353, which is located near the calcium and triadin/junctin binding sites. Although phosphorylation increased the calcium binding capacity of calsequestrin nearly 2-fold, it did not alter calsequestrin polymerisation, its binding to triadin or junctin or inhibition of ryanodine receptor activity at 1 mM luminal calcium. Phosphorylation was required for calsequestrin binding to junctin when calcium concentration was low (100 nM), and ryanodine receptors were activated by dephosphorylated calsequestrin when it bound to triadin alone. These novel data shows that phosphorylated calsequestrin is required for high capacity calcium buffering and suggest that ryanodine receptor inhibition by calsequestrin is mediated by junctin.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19230141     DOI: 10.1016/j.ceca.2008.01.005

Source DB:  PubMed          Journal:  Cell Calcium        ISSN: 0143-4160            Impact factor:   6.817


  22 in total

1.  Calsequestrin content and SERCA determine normal and maximal Ca2+ storage levels in sarcoplasmic reticulum of fast- and slow-twitch fibres of rat.

Authors:  Robyn M Murphy; Noni T Larkins; Janelle P Mollica; Nicole A Beard; Graham D Lamb
Journal:  J Physiol       Date:  2008-11-24       Impact factor: 5.182

Review 2.  Junctin - the quiet achiever.

Authors:  Angela Dulhunty; Lan Wei; Nicole Beard
Journal:  J Physiol       Date:  2009-07-01       Impact factor: 5.182

Review 3.  Organellar calcium buffers.

Authors:  Daniel Prins; Marek Michalak
Journal:  Cold Spring Harb Perspect Biol       Date:  2011-03-01       Impact factor: 10.005

4.  On the footsteps of Triadin and its role in skeletal muscle.

Authors:  Claudio F Perez
Journal:  World J Biol Chem       Date:  2011-08-26

5.  The elusive role of the SPRY2 domain in RyR1.

Authors:  HanShen Tae; Lan Wei; Hermia Willemse; Shamaruh Mirza; Esther M Gallant; Philip G Board; Robert T Dirksen; Marco Giovani Casarotto; Angela Dulhunty
Journal:  Channels (Austin)       Date:  2011-03-01       Impact factor: 2.581

6.  Phosphorylation of human calsequestrin: implications for calcium regulation.

Authors:  Emiliano J Sanchez; Gerhard R Munske; Angela Criswell; Hendrik Milting; A Keith Dunker; Chulhee Kang
Journal:  Mol Cell Biochem       Date:  2011-03-17       Impact factor: 3.396

7.  Junctin and triadin each activate skeletal ryanodine receptors but junctin alone mediates functional interactions with calsequestrin.

Authors:  Lan Wei; Esther M Gallant; Angela F Dulhunty; Nicole A Beard
Journal:  Int J Biochem Cell Biol       Date:  2009-05-04       Impact factor: 5.085

8.  β-Adrenergic stimulation increases the intra-sarcoplasmic reticulum Ca2+ threshold for Ca2+ wave generation.

Authors:  Timothy L Domeier; Joshua T Maxwell; Lothar A Blatter
Journal:  J Physiol       Date:  2012-09-17       Impact factor: 5.182

9.  Sarcolipin and ubiquitin carboxy-terminal hydrolase 1 mRNAs are over-expressed in skeletal muscles of alpha-tocopherol deficient mice.

Authors:  Vihas T Vasu; Sean Ott; Brad Hobson; Vania Rashidi; Saji Oommen; Carroll E Cross; Kishorchandra Gohil
Journal:  Free Radic Res       Date:  2009-02

10.  Adverse effects of doxorubicin and its metabolic product on cardiac RyR2 and SERCA2A.

Authors:  Amy D Hanna; Alex Lam; Steffi Tham; Angela F Dulhunty; Nicole A Beard
Journal:  Mol Pharmacol       Date:  2014-08-08       Impact factor: 4.436

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.